Herbert Temmes

Hannover, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis - Results of the randomised controlled POWER@MS1 trial.

Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis - Results of the randomised controlled POWER@MS1 trial.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 12, 2025

Factors influencing health behavior changes in people with early multiple sclerosis: process evaluation of the multicenter randomized controlled POWER@MS1 trial.

Factors influencing health behavior changes in people with early multiple sclerosis: process evaluation of the multicenter randomized controlled POWER@MS1 trial.

Journal: Frontiers in neurology

Published: May 27, 2025

MS brain health quality standards: a survey on the reality in clinical practice in Germany.

MS brain health quality standards: a survey on the reality in clinical practice in Germany.

Journal: Neurological research and practice

Published: December 20, 2023

Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study.

Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study.

Journal: Vaccines

Published: November 08, 2023

Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany - Baseline characteristics of the POWER@MS1 randomised controlled trial.

Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany - Baseline characteristics of the POWER@MS1 randomised controlled trial.

Journal: Multiple sclerosis and related disorders

Published: April 18, 2023

Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study.

Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study.

Journal: Journal of clinical medicine

Published: April 13, 2023

SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.

SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.

Journal: The Lancet regional health. Europe

Published: September 12, 2022

'That would have been the perfect thing after diagnosis': development of a digital lifestyle management application in multiple sclerosis.

'That would have been the perfect thing after diagnosis': development of a digital lifestyle management application in multiple sclerosis.

Journal: Therapeutic advances in neurological disorders

Published: April 14, 2022

Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies.

Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies.

Journal: Multiple sclerosis and related disorders

Published: February 11, 2022

Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol.

Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol.

Journal: BMJ open

Published: January 26, 2022

Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1).

Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1).

Journal: BMJ open

Published: February 17, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026